RxDoctor Payments Data

Jessy Woods, MD

Internal Medicine · Terre Haute, INNPI 1427275353

Payments from drug & device makers

$635in general payments, 2019–2025

Across 31 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$167
  • Pfizer$43
  • Gilead$42
  • Covis Pharma GmbH$40
  • Grifols USA, LLC$40
  • Abbott$38
  • plus $264 from 10 others

What the payments were for

  • Food & beverage$635100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$635 in reported general payments places this provider in the 70th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$437
Medicare patients
19
Services billed
35

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$75,727
FarxigaDapagliflozin Propanediol57$66,077
JardianceEmpagliflozin44$54,474
JanuviaSitagliptin Phosphate18$23,772
LinzessLinaclotide18$22,741
Nurtec OdtRimegepant Sulfate12$22,117
TrulicityDulaglutide14$19,288
XareltoRivaroxaban14$16,582
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,650
EliquisApixaban14$9,404
Advair HfaFluticasone Propion/Salmeterol24$7,814
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$6,650
Breo ElliptaFluticasone/Vilanterol14$5,359
Gabapentin165$4,133
Albuterol Sulfate HfaAlbuterol Sulfate157$3,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$35$75,72775 claims
AstraZenecaFarxiga$32$66,07757 claims
PfizerNurtec Odt, Eliquis$43$31,52126 claims
Lilly USA, LLCTrulicity$18$19,28814 claims
GSKTrelegy Ellipta, Breo Ellipta$167$17,00928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →